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Abstract
Based on observational studies there is a linear increase in cardiovascular risk with higher systolic 
blood pressure, yet clinical trials have not shown benefit across all systolic blood pressure 
categories. We assessed if troponin-T measured using high-sensitivity assay was associated with 
cardiovascular disease within systolic blood pressure categories in 11191 Atherosclerosis Risk in 
Communities study participants. Rested sitting systolic blood pressure by 10-mmHg increments 
and troponin categories were identified. Incident heart failure hospitalization, coronary heart 
disease and stroke were ascertained over a median of 12 years after excluding individuals with 
corresponding disease. Approximately 53% of each type of cardiovascular event occurred in 
individuals with systolic blood pressure<140 mmHg and troponin-T≥3ng/L. Higher troponin-T 
was associated with increasing cardiovascular events across most systolic blood pressure 
categories. The association was strongest for heart failure and least strong for stroke. There was no 
similar association of systolic blood pressure with cardiovascular events across troponin-T 
categories. Individuals with troponin-T≥3ng/L and systolic blood pressure<140mmHg had higher 
cardiovascular risk compared to those with troponin-T<3ng/L and systolic blood pressure 140-159 
mmHg.
Higher troponin-T levels within narrow systolic blood pressure categories portend increased 
cardiovascular risk, particularly for heart failure. Individuals with lower systolic blood pressure 
but measurable troponin-T had greater cardiovascular risk compared to those with suboptimal 
systolic blood pressure but undetectable troponin-T. Future trials of systolic hypertension may 
benefit by using high-sensitivity troponin-T to target high-risk patients.
Keywords
High-sensitivity troponin-T; Hypertension; Atherosclerosis Risk In Communities (ARIC) Study; 
Cardiovascular disease; Heart failure
Introduction
Elevated blood pressure is a modifiable risk factor strongly associated with coronary heart 
disease (CHD), stroke and heart failure (HF) 1, 2. Observational studies have shown that 
beginning at a blood pressure (BP) of 115/75 mmHg, the risk for cardiovascular (CV) 
disease doubles with each 20/10-mmHg increment in BP 3. Similarly, the presence of 
hypertension (HTN) classifies an individual as having “Stage A” HF, i.e. at increased risk 
for future development of HF 4.
Clinical trials have generally shown that BP reduction in individuals with HTN resulted in 
decreased CV disease incidence, including HF 5. While BP lowering interventions are 
clearly associated with improved outcomes at systolic BP (SBP) >150 mmHg, recent studies 
evaluating intensive control of BP have shown no benefit 2. For example, in the Action to 
Control Cardiovascular Risk in Diabetes trial, SBP reduction in diabetics to <120 mmHg did 
not lower CV events when compared with lowering SBP to <140 mmHg 6. In fact, the 2014 
report from the Panel Members Appointed to the Eighth Joint National Committee has 
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revised the BP management targets in HTN such that for individuals 60 years or older, 
therapy is now advocated only for SBP ≥150 mmHg or diastolic BP ≥90 mmHg 2. 
Epidemiological studies, on the other hand, have shown a monotonic, linear increase in CV 
risk with increasing SBP starting at 115 mmHg 3. This disconnect between epidemiological 
studies and clinical trial results suggests that the risk associated with intensive 
antihypertensive treatment negates the potential benefit of lower BP when considering the 
population at large, although a recent meta-analysis suggested that individuals at highest risk 
may benefit from aggressive BP management 7. Hence, an individual's attributes may 
modify the putative benefits of BP lowering, in which case a better characterization may be 
important to assess the role for more-intensive/personalized BP management.
Recently, cardiac troponin-T measured by high sensitivity assay (cTnT) has been shown to 
detect subclinical cardiac injury 8 and to predict CHD, HF, mortality and stroke in 
epidemiological studies 9-11. While atherosclerosis mediates a significant proportion of the 
HTN-associated adverse CV events, evidence of myocardial injury from HTN in the absence 
of atherosclerosis also is well documented 12, 13. Furthermore, among individuals with left 
ventricular hypertrophy (LVH) measurable cTnT (≥3 ng/L) was associated with 
significantly increased incident HF and CV death compared to individuals with cTnT below 
the lower limit of measurement (<3 ng/L) 14, indicating that cTnT can be informative even 
in the presence of LVH. Therefore, we hypothesized that measurement of cTnT would 
improve risk stratification for incident CV disease (CHD, stroke and first HF 
hospitalization) across the range of SBP.
Methods
Study Population, Blood Pressure Measurement and Troponin Assay
Of 11,656 participants who attended visit 4 of the Atherosclerosis Risk in Communities 
(ARIC) study, a population based study of cardiovascular disease incidence (see 
supplemental methods for additional details), 11,191 were eligible for our analysis after 
exclusions (S. figure 1). For each outcome of interest, individuals with prevalent disease 
were excluded (for example, for incident HF, those with prevalent HF were excluded). 
Certified technicians used a random-zero sphygmomanometer to measure 2 BP readings in 
the sitting position after 5 minutes of rest and an average BP of the 2 measurements was 
recorded 15. Hypertension was defined as SBP ≥140 mmHg, diastolic BP ≥90 mmHg or use 
of antihypertensive medications. We used the following pre-specified categories of SBP for 
our analysis: <120, 120-129, 130-139, 140-149, 150-159 and ≥160 mmHg.
The specific details regarding the cTnT assay have been previously published 9. Briefly, 
cTnT concentrations were measured with a high-sensitivity assay, Elecsys Troponin T 
(Roche Diagnostics®), on an automated Cobas e411 analyzer with a lower limit of 
measurement of 3 ng/L. Similar to our previous analyses, we used 5 pre-specified categories 
of cTnT (<3, 3-5, 6-8, 9-13, and ≥14 ng/L) 9.
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Ascertainment of incident cardiovascular events
All potential CV events were adjudicated based on published criteria 16, 17. Incident CHD 
was defined as hospitalization for myocardial infarction, definite coronary death, coronary 
revascularization procedure, or silent myocardial infarction as confirmed by 
electrocardiogram (ECG). Hard CHD events excluded coronary revascularization 
procedures. Stroke was defined as sudden or rapid onset of neurological symptoms lasting 
for >24 hours or leading to death, in the absence of evidence for a nonstroke cause 16. 
Incident HF was defined as the first HF hospitalization identified with International 
Classification of Diseases Code of 428.× (Ninth Revision) or I50 (Tenth Revision) in any 
position on the hospital discharge list or a death certificate with death from HF in any 
position 18.
Statistical analysis
Our main outcomes of interest were incident CHD (total or hard CHD), stroke (all types) 
and first HF hospitalization. All presented tests were 2-tailed and a p-value <0.05 was 
considered statistically significant. Using Cox proportional hazards model, the associations 
between categories of cTnT or SBP and incident events were assessed using a model 
adjusted for age, race, gender, antihypertensive medication use, log of N terminal pro-B-
type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate, diabetes, fasting 
glucose, total/high-density lipoprotein cholesterol ratio, body mass index, current cigarette 
smoking and CV disease status. Follow up time ended when the participant had an outcome, 
died, was lost to follow-up, or survived until December 31st 2009.
We used 2 reference groups in our main analysis, (i) cTnT <3 ng/L and SBP <120 mmHg, 
and (ii) cTnT <3 ng/L and SBP 140-159 mmHg. The second reference group was used to 
examine whether individuals with measurable cTnT at levels of SBP where therapy will not 
be required currently had increased CV risk compared to those with higher SBP but cTnT 
below the lower limit of measurement. We performed the following sensitivity analyses: 
adjusted the model further for LVH as determined by ECG; used each SBP category and 
cTnT<3 ng/L as a reference; used cTnT ≤5 ng/L as a reference because cTnT of 5 ng/L is 
considered the limit of detection; and modeled cTnT as a continuous variable by keeping the 
same categories of SBP. Finally, using 2 different references in separate analyses (SBP <120 
mmHg and cTnT <3 ng/L and SBP 140-159 mmHg and cTnT<3 ng/L), we performed 
subgroup analyses by the status of antihypertensive medication use.
Results
Baseline characteristics
The mean age of the study population was 63 (standard deviation, 6) years, approximately 
22% were African Americans and 56% were women (Table 1). The mean BP was 128/71 
(19/10) mmHg, mean cTnT 7.5 (17) ng/L and median NT-proBNP 68 (interquartile range, 
33-134) pg/mL. Approximately 3.5% of participants had ECG-diagnosed LVH and 44% 
were using antihypertensive medications. Increasing cTnT levels were associated with 
increasing age, male sex, increasing NT-proBNP level, diabetes, antihypertensive 
medication use and with declining estimated glomerular filtration rate across each category 
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of SBP and with higher prevalence of ECG-assessed LVH across most SBP categories 
(Table S1).
Cardiovascular outcomes
There were a total of 1,144 incident HF hospitalizations, 1,377 incident CHD events, 
including 857 incident hard CHD events and 526 incident stroke events, resulting in incident 
rates of 9.9, 12.1, 7.2 and 4.3 per 1000 person-years, respectively. Approximately 53% of 
each CV outcome occurred in individuals with SBP<140 mmHg and cTnT≥3 ng/L.
Increasing cTnT was significantly associated with increasing incidence of HF 
hospitalization for each category of SBP (Table 2 and Figure). The association with HF was 
very strong, with significant associations starting even at lower levels of cTnT across most 
SBP categories. There were similar but attenuated associations for CHD and hard CHD 
(Figures S2 A&B) and further weaker association for stroke, particularly at lower SBP 
categories (Figure S2 C). Compared to individuals with SBP <120 mmHg and cTnT <3 
ng/L, those with SBP 130-139 mmHg and cTnT ≥14 ng/L had hazard ratios (HR) of 4.1 
(95% confidence interval [CI], 2.6-6.4) for incident HF hospitalization; 2.0 (95% CI, 
1.3-2.9) for CHD; 1.8 (95% CI, 1.1-2.9) for hard CHD; and 1.9 (95% CI, 1.0-3.6) for stroke 
(Table 2). In contrast, the trend and the strength of associations of increasing SBP with each 
CV event across each cTnT category were not as robust (Table 2).
When the reference was changed to SBP 140-159 mmHg and cTnT <3 ng/L, there were 
similar trends for CV events (Table 3) with individuals with cTnT ≥3 ng/L (especially those 
with higher cTnT ranges) having significantly increased hazards for CV events. For 
example, individuals with SBP 130-139 mmHg and cTnT ≥14 ng/L had HRs of 3.7 (95% 
CI, 2.3-6.1) for incident HF hospitalization, 1.7 (95% CI, 1.1-2.6) for CHD, 2.2 (95% CI, 
1.2-4.0) for hard CHD, and 1.8 (95% CI, 0.9-3.7) for stroke.
In additional analyses, similar results were obtained when the model was further adjusted for 
ECG-diagnosed LVH (Table S2) or when the reference was changed to each SBP category 
and cTnT<3 ng/L (data not presented). We obtained similar results when cTnT ≤5 ng/L 
replaced cTnT <3 ng/L (Table S3). When cTnT was modeled as a continuous variable, there 
were significant hazards for HF, CHD and hard CHD across each category of SBP per 1-
standard deviation increase in cTnT (17 ng/L) (Table S4). Results were less robust for 
stroke. Finally, when we analyzed the hazards for the different end points stratified by use of 
anti-hypertensive medications the results were for the most part consistent with the primary 
analysis whether we used SBP <120 mmHg and cTnT <3 ng/L or SBP 140-159 and cTnT 
<3 ng/L as the reference (Tables S5 A&D and S6 A&D), except for CHD outcomes (Tables 
S5 B-C and S6 B-C).
Discussion
In these analyses, we show that individuals with higher levels of cTnT have significantly 
increased risk for incident CV events within narrow SBP categories, with the strongest 
hazards observed in individuals with the highest cTnT levels in each SBP category. The 
association was particularly strong for HF. While the association between cTnT and various 
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CV events has been previously described in several studies 10, 12 including the ARIC 
study 9, 11, the value of measuring high-sensitivity troponin-T as a marker of the effect of 
BP on incident CV outcomes has not been previously reported. In a study of 176 Japanese 
hypertensive individuals free of CV disease, troponin-T ≥20 ng/L was independently 
associated with hospitalization for CV or cerebrovascular disease (HR 6.58, p <0.0001) 
compared to 39 normal controls 19; however this study did not use the higher sensitivity 
assay. Because cTnT is a marker of myocardial injury (an important step in the 
pathophysiology of adverse CV events such as HF), we hypothesized that cTnT assessment 
would identify those individuals in whom risk factors such as HTN has a particularly 
adverse impact and render them at higher risk for incident CV events. Indeed, one of the 
more important findings of our study was that among individuals with SBP that will not 
require therapy per current US guidelines 2 (e.g., <140 mmHg), those with increased cTnT 
levels had significantly higher hazards for CV events when compared to those with 
suboptimal SBP (e.g., SBP 140-159 mmHg) but cTnT below the lower limit of measurement 
(Table 3).
The association with stroke was not as robust, particularly at lower BP categories, likely 
related to the smaller number of individuals with incident stroke and perhaps also is a 
reflection of other important pathophysiological mechanisms of stroke. On the other hand, 
increase in SBP within each cTnT category was not generally associated with a significant 
trend for increasing risk for incident CV events (Table 2). This suggests that the effect of 
SBP was attenuated once we accounted for cTnT, indicating that myocardial injury may 
mediate the effects of SBP on HF and, to a lesser extent, on other CV endpoints. Therefore, 
cTnT may serve as a sensitive surrogate to identify individuals with elevated BP who have 
subclinical cardiac end-organ injury and hence are at greater risk for incident CV disease, 
especially HF. If replicated, such an observation has important clinical and research 
implications.
Elevated BP is a well-established risk factor for CV disease and interventions that lower BP 
have generally decreased CV events 5. This benefit has not been uniformly observed across 
all the BP and age ranges. The authors of the 2014 US guidelines for management of HTN 
concluded that while there is strong evidence to initiate pharmacologic treatment for 
individuals with BP of 150/90 mmHg or higher, the same level of evidence was not present 
at lower SBPs 2. The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure recommended a goal BP of 
<130/80 mmHg in individuals with diabetes and chronic kidney disease as an attempt to 
identify high-risk groups who would likely derive the most benefit from intensive BP 
treatment 1. Although specific to diabetics, the Action to Control Cardiovascular Risk in 
Diabetes failed to show that intensive lowering of SBP (a mean of 119.3 mmHg was 
achieved) was superior to traditional management of SBP (a mean SBP of 133.5 mmHg was 
achieved in the placebo arm) among diabetics 6. Similarly, a lower BP goal (e.g., <130/80 
mmHg) did not significantly lower renal or CV end points in patients with chronic kidney 
disease 2. On the other hand, a meta-analysis of epidemiological studies showed that the risk 
for CV disease doubles with each 20/10 mmHg increase in BP, beginning at BP of 115/75 
mmHg 3, while another meta-analysis documented an increased risk of stroke in a dose-
response manner as BP increased from 120-129/80-84 to 130-139/85-89 mmHg 20. 
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Therefore, the literature reflects a clear disconnect between epidemiological studies and 
clinical trials, viz. the benefits of BP reduction at different BP levels. A deeper 
understanding of the circumstances under which the risk of the intervention exceeds the 
benefit of BP lowering as benchmarked against the population at large is needed. Identifying 
susceptible individuals, for instance those further advanced in the pathophysiological 
cascade of adverse CV events, may help optimize the risk to benefit balance and provide 
opportunities to personalize the management of elevated BP. Indeed a recent meta-analysis 
of clinical trials of antihypertensive medications showed that as the baseline CV risk 
increased there was progressively greater absolute risk reductions in major CV events 7.
Troponin T is a sensitive marker of myocardial injury 8, which is likely an important 
contribution in the pathogenesis of adverse CV events such as HF. This study found that 
approximately 53% of each type of CV event occurred in individuals with SBP<140 mmHg 
and cTnT≥3 ng/L. Taken together with other data such as that from the Dallas Heart Study 
where measurable cTnT (≥3 ng/L) was associated with further increased hazards for adverse 
CV events among individuals with LVH 14, we believe that future clinical trials can benefit 
from the use of cTnT to help characterize susceptible individuals in whom therapy options 
can be tested to personalize the management of elevate BP and the prevention of its 
sequelae.
The strengths of our study include a well-characterized large biracial population (majority 
women) followed for a median of 12 years with careful adjudication of incident CV events. 
There were some limitations as well. Some individuals with measurable cTnT and low SBP 
(e.g., <140 mmHg) could possibly have had subclinical left ventricular dysfunction, which 
could not be evaluated due to lack of echocardiography data. All individuals in our analysis 
were asymptomatic and hence echocardiogram would not have been clinically 
recommended 21. Hence despite our inability to evaluate for subclinical left ventricular 
dysfunction clinically our results will still have significant value. Furthermore, since the 
ARIC study conducts ongoing and comprehensive surveillance for CV-related 
hospitalizations and outcomes of its cohort 22, it is less likely that individuals with 
significant left ventricular dysfunction, who would most likely be symptomatic would have 
been missed. Additionally, one may expect use of BP lowering medications such as 
angiotensin converting enzyme inhibitors in these individuals, but our subgroup analyses 
stratified by antihypertensive medication use showed results similar to that of the overall 
population for most end points and SBP categories. We further showed that cTnT remains 
associated with CV events independent of NT-proBNP and other CV risk factors. The 
original ARIC cohort was selected based on random sampling of participants. It is possible 
that visit 4 participants were a healthier subcohort of the original sample. However, if the 
association is strong in a healthier population (as we report) then it is likely that the 
association would have persisted with a sicker population as well. Finally, the observational 
design of our study also requires that our results be interpreted with caution, particularly in 
contrast to the information emerging from clinical trials that have the benefit of 
randomization. Although prospective and rigorously standardized, as well as analyzed with 
inclusion of pertinent covariates, residual confounding cannot be ruled out.
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cTnT is strongly associated with CV events across all SBP categories including 
“prehypertensives”. By perhaps identifying individuals with subclinical myocardial injury 
cTnT may help identify the individuals most compromised in their pathophysiology, and 
thus most prone to incident CV events. Future clinical trials should consider cTnT as a 
marker to identify subjects at higher risk for CV events in whom aggressive risk factor 
modification can be tested.
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High-sensitivity troponin T is associated with increased adverse cardiovascular events 
across the range of systolic blood pressure within 10 mm Hg systolic blood pressure 
increments.
What is relevant?
The risk for incident adverse cardiovascular end points of individuals with cardiovascular 
risk factors such as systolic blood pressure can be better characterized by measuring a 
marker of myocardial injury (troponin T). Such approaches may contribute to personalize 
the delivery of care in individuals with elevated blood pressure by identifying those 
further advanced in the pathophysiological cascade toward incident cardiovascular 
events.
Summary
Clinical trials are needed to test the efficacy of aggressive risk factor modification in 
those with subclinical myocardial injury indexed by elevated, high-sensitivity troponin-T.
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Hazard for heart failure by systolic blood pressure and high-sensitivity cardiac troponin-T 
categories
The figure shows hazards for incident heart failure hospitalization with increasing systolic 
blood pressure and high-sensitivity cardiac troponin-T in a fully adjusted model.
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Table 1
Baseline characteristics in the study population [n=11,191]
Characteristic *Study population
Age (years) 62.8±5.7
African American 2,477 (22.1)
Women 6,263 (55.9)
Current smokers 1,650 (14.8)
BMI (kg/m2) 28.8±5.6
Blood glucose (mg/dL) 111±39
Total cholesterol (mg/dL) 200.8±37.1
HDL-C (mg/dL) 50.0±16.5
Total /HDL-C ratio 4.4±1.5
LDL-C (mg/dL) 122.6±33.4
Triglycerides (mg/dL) 122 (89–174)
hs-CRP (mg/L) 2.5 (1.1–5.5)
Blood pressure (mmHg) 128/71±19/10
Mean BP (mmHg) 99.3±13.1
Pulse pressure (mmHg) 56.6±16








BMI = body mass index, BP = blood pressure, cTnT = high-sensitivity cardiac troponin-T, eGFR = estimated glomerular filtration rate, HDL-C = 
high-density lipoprotein cholesterol, hs-CRP = high-sensitivity C-reactive protein, LDL-C = low-density lipoprotein cholesterol, LVH = left 
ventricular hypertrophy, NT-proBNP = N-terminal pro–B-type natriuretic peptide.
*
Data presented as mean±SD or median (interquartile range) for continuous variables and n (%) for dichotomous variables.
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Table 2
Incident hazard rate ratios of cardiovascular outcomes in the study population across systolic blood pressure 
and troponin-T categories (reference group: systolic blood pressure <120 mmHg and troponin T <3 ng/L)
SBP (mmHg) [n] <3 3–5 cTnT (ng/L) [n] 6–8 9–13 ≥14
P for trend
*
HF [10416] [3374] [2647] [2117] [1405] [873]
<120 [3815] reference 1.3 (0.9-2.0) 2.0 (1.3-2.9) 2.6 (1.7-4.0) 5.4 (3.6-8.0) <0.001
120-129 [2380] 1.4 (0.9-2.2) 1.5 (1.0-2.3) 2.1 (1.4-3.1) 2.0 (1.2-3.1) 5.8 (3.7-9.0) <0.001
130-139 [1768] 1.3 (0.8-2.0) 1.6 (1.0-2.5) 2.5 (1.6-3.8) 2.9 (1.8-4.5) 4.1 (2.6-6.4) <0.001
140-149 [1179] 1.2 (0.7-2.1) 2.3 (1.5-3.6) 2.1 (1.3-3.3) 2.7 (1.7-4.3) 4.3 (2.7-6.8) 0.002
150-159 [656] 0.9 (0.4-1.9) 1.0 (0.5-2.0) 2.1 (1.1-3.7) 3.6 (2.2-5.7) 5.2 (3.2-8.5) <0.001
≥160 [618] 1.4 (0.8-2.6) 2.1 (1.2-3.9) 2.7 (1.7-4.5) 3.0 (1.9-4.9) 3.8 (2.3-6.3) <0.001
P for trend 
† 0.595 0.069 0.572 0.337 0.271
CHD [10518] [3453] [2666] [2121] [1397] [881]
<120 [3831] reference 1.0 (0.8-1.4) 1.2 (0.8-1.6) 1.3 (0.9-1.8) 1.8 (1.2-2.5) 0.570
120-129 [2373] 1.1 (0.8-1.5) 1.1 (0.8-1.6) 1.3 (0.9-1.8) 1.3 (0.9-1.9) 2.5 (1.7-3.6) 0.010
130-139 [1804] 1.2 (0.8-1.7) 1.4 (1.0-2.0) 1.4 (0.9-1.9) 1.6 (1.1-2.3) 2.0 (1.3-2.9) 0.062
140-149 [1203] 1.2 (0.8-1.9) 1.4 (1.0-2.1) 1.5 (1.0-2.2) 1.6 (1.1-2.4) 2.1 (1.4-3.2) 0.092
150-159 [658] 1.0 (0.6-1.8) 1.2 (0.7-2.0) 1.9 (1.2-3.0) 1.8 (1.2-2.9) 2.7 (1.6-4.4) 0.040
≥160 [649] 1.4 (0.8-2.5) 1.0 (0.5-1.9) 2.1 (1.4-3.2) 2.7 (1.8-3.9) 2.4 (1.5-3.8) 0.021
P for trend 
† 0.577 0.569 0.067 0.046 0.640
Hard CHD [10754] [3474] [2712] [2183] [1453] [932]
<120 [3907] reference 1.0 (0.6-1.4) 1.0 (0.7-1.5) 1.2 (0.8-1.9) 2.0 (1.3-3.0) 0.217
120-129 [2434] 1.0 (0.7-1.6) 0.9 (0.6-1.4) 1.3 (0.9-1.9) 1.2 (0.8-1.9) 2.6 (1.7-4.1) 0.001
130-139 [1842] 1.0 (0.6-1.6) 1.1 (0.7-1.8) 1.1 (0.7-1.8) 1.4 (0.8-2.3) 1.8 (1.1-2.9) 0.155
140-149 [1231] 0.9 (0.5-1.5) 1.1 (0.6-1.8) 1.2 (0.7-2.0) 1.0 (0.6-1.8) 2.0 (1.2-3.3) 0.006
150-159 [672] 0.7 (0.3-1.6) 0.8 (0.4-1.7) 1.8 (1.0-3.3) 1.7 (1.0-2.9) 3.3 (1.9-5.6) 0.004
≥160 [668] 1.2 (0.7-2.4) 1.4 (0.7-2.7) 1.4 (0.8-2.5) 2.1 (1.3-3.4) 2.1 (1.2-3.5) 0.724
P for trend 
† 0.884 0.841 0.253 0.391 0.418
Stroke [11042] [3522] [2749] [2241] [1513] [1017]
<120 [4030] reference 1.1 (0.7-1.9) 0.6 (0.3-1.1) 1.4 (0.8-2.5) 1.1 (0.6-2.3) 0.178
120-129 [2489] 1.2 (0.7-2.0) 1.3 (0.7-2.2) 1.7 (1.0-2.9) 1.5 (0.8-2.7) 1.4 (0.7-2.9) 0.530
130-139 [1889] 1.2 (0.7-2.1) 1.1 (0.6-2.0) 1.6 (0.9-2.8) 1.8 (1.0-3.4) 1.9 (1.0-3.6) 0.514
140-149 [1262] 1.0 (0.5-2.0) 1.8 (1.0-3.3) 1.5 (0.8-2.7) 1.5 (0.8-3.0) 3.0 (1.6-5.6) 0.173
150-159 [690] 1.1 (0.4-2.5) 1.0 (0.4-2.3) 1.3 (0.5-3.2) 3.2 (1.7-5.9) 2.4 (1.1-4.8) 0.037
≥160 [682] 1.9 (1.0-3.8) 2.2 (1.1-4.5) 1.2 (0.6-2.7) 1.9 (1.0-3.7) 3.3 (1.8-6.1) 0.318
P for trend 
† 0.674 0.483 0.044 0.181 0.014
Data presented are hazard ratios (95% confidence interval) as calculated using Cox proportional hazards model after adjusting for age, race, gender, 
antihypertensive medication use, log NT-proBNP, renal function (estimated glomerular filtration rate), diabetes status, fasting glucose, total 
cholesterol/HDL-C ratio, BMI, current cigarette smoking and previous CV disease status (except the outcome for each model; e.g., for HF, we 
adjusted for CHD and stroke).
CHD = coronary heart disease, CV = cardiovascular, HF = heart failure, SBP = systolic blood pressure, other abbreviations similar to Table 1.
Numbers in parentheses indicate number of participants.
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P for trend was calculated based on the results of Wald chi-square test on linearity hypothesis of ordered cTnT or SBP categories.
*
P for trend across rows (i.e., trend across increasing cTnT at each SBP category)
†
P for trend across columns (i.e., trend across increasing SBP at each cTnT category)
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Table 3
Incident hazard rate ratios of cardiovascular outcomes in the study population across systolic blood pressure 
and troponin-T categories (reference group: systolic blood pressure 140-159 mmHg and troponin T <3 ng/L)
SBP (mmHg) <3 3–5 cTnT (ng/L) 6–8 9–13 ≥14 P for trend*
HF
<120 0.9 (0.6-1.5) 1.2 (0.7-1.9) 1.8 (1.1-2.8) 2.4 (1.5-3.8) 4.9 (3.1-7.7) <0.001
120-129 1.3 (0.8-2.1) 1.4 (0.9-2.2) 1.9 (1.2-3.0) 1.8 (1.1-3.0) 5.3 (3.2-8.6) <0.001
130-139 1.2 (0.7-1.9) 1.4 (0.9-2.4) 2.3 (1.4-3.6) 2.6 (1.6-4.3) 3.7 (2.3-6.1) <0.001
140-159 reference 1.6 (1.0-2.6) 1.9 (1.2-3.0) 2.8 (1.8-4.4) 4.2 (2.7-6.7) <0.001
≥160 1.3 (0.7-2.4) 1.9 (1.0-3.6) 2.5 (1.5-4.3) 2.7 (1.6-4.6) 3.5 (2.0-5.9) <0.001
CHD
<120 0.9 (0.6-1.2) 0.9 (0.6-1.3) 1.0 (0.7-1.4) 1.1 (0.8-1.7) 1.5 (1.0-2.3) 0.570
120-129 1.0 (0.6-1.4) 1.0 (0.7-1.5) 1.1 (0.7-1.6) 1.1 (0.8-1.7) 2.1 (1.4-3.3) 0.010
130-139 1.0 (0.7-1.6) 1.2 (0.8-1.8) 1.2 (0.8-1.8) 1.4 (0.9-2.1) 1.7 (1.1-2.6) 0.062
140-159 reference 1.2 (0.8-1.7) 1.4 (0.9-2.1) 1.5 (1.0-2.2) 2.0 (1.3-3.0) 0.172
≥160 1.3 (0.7-2.2) 0.8 (0.4-1.7) 1.8 (1.1-2.9) 2.3 (1.5-3.5) 2.1 (1.3-3.4) 0.021
Hard CHD
<120 1.3 (0.8-2.1) 1.2 (0.7-2.0) 1.3 (0.7-2.1) 1.6 (0.9-2.7) 2.5 (1.4-4.3) 0.217
120-129 1.3 (0.7-2.2) 1.1 (0.6-2.0) 1.6 (1.0-2.7) 1.5 (0.8-2.7) 3.3 (1.9-5.7) 0.001
130-139 1.3 (0.7-2.3) 1.4 (0.8-2.5) 1.4 (0.8-2.5) 1.7 (0.9-3.1) 2.2 (1.2-4.0) 0.115
140-159 reference 1.2 (0.7-2.2) 1.8 (1.0-3.0) 1.6 (0.9-2.8) 3.1 (1.8-5.3) 0.010
≥160 1.6 (0.8-3.3) 1.7 (0.8-3.6) 1.8 (0.9-3.5) 2.6 (1.4-4.7) 2.6 (1.4-4.9) 0.724
Stroke
<120 1.0 (0.5-1.7) 1.1 (0.6-2.0) 0.5 (0.3-1.1) 1.4 (0.7-2.6) 1.1 (0.5-2.4) 0.178
120-129 1.1 (0.6-2.1) 1.2 (0.6-2.3) 1.7 (0.9-3.0) 1.4 (0.7-2.8) 1.3 (0.6-2.9) 0.530
130-139 1.2 (0.6-2.3) 1.1 (0.5-2.1) 1.5 (0.8-2.9) 1.8 (0.9-3.5) 1.8 (0.9-3.7) 0.514
140-159 reference 1.4 (0.8-2.7) 1.4 (0.7-2.6) 2.1 (1.2-3.9) 2.6 (1.4-4.9) 0.583
≥160 1.8 (0.9-4.0) 2.1 (1.0-4.6) 1.2 (0.5-2.7) 1.8 (0.9-3.8) 3.2 (1.6-6.3) 0.318
Data presented similar to that in Table 2.
Numbers of participants in each group are same as in Table 2.
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